Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PUMA BIOTECHNOLOGY, INC. (PBYI)

Puma Biotechnology raises 2026 net income outlook; Q3 net income falls to $6.0 million

Mixed Impact 4 of 5 earnings Written later

Puma Biotechnology reported third-quarter 2026 results, with total revenue up slightly to $55.1 million from $54.5 million while GAAP net income fell to $6.0 million from $8.8 million. The company raised its full-year 2026 net income outlook to $20–22 million from $17–20 million, but its total revenue outlook was narrowed, with the top end lowered to $227 million from $231 million.

Key points

  • Q3 2026 net product revenue was $54.1 million, up from $51.9 million in Q3 2025; royalty revenue was $1.0 million, down from $2.6 million.
  • Q3 2026 GAAP net income was $6.0 million, or $0.11 per diluted share, compared with $8.8 million, or $0.17 per diluted share, in Q3 2025.
  • Full-year 2026 net income outlook was raised to $20–22 million from $17–20 million; total revenue outlook is $224–227 million versus $224–231 million previously.
  • Cash, cash equivalents and marketable securities were $108.5 million at September 30, 2026.

The filing

CompanyPUMA BIOTECHNOLOGY, INC. (PBYI)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:13 PM ET
Accession number0001437749-26-035279

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.